{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:11:41Z","timestamp":1792059101981,"version":"4.4.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.35792","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T04:08:59Z","timestamp":1612238939000},"page":"e2035792","source":"Crossref","is-referenced-by-count":86,"title":["Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019"],"prefix":"10.1001","volume":"4","author":[{"given":"Rozalina G.","family":"McCoy","sequence":"first","affiliation":[{"name":"Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"},{"name":"Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly K.","family":"Van Houten","sequence":"additional","affiliation":[{"name":"Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"},{"name":"Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[{"name":"Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"},{"name":"Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar Karaca","family":"Mandic","sequence":"additional","affiliation":[{"name":"Department of Finance and Medical Industry Leadership Institute, Carlson School of Management, University of Minnesota, Minneapolis"},{"name":"National Bureau of Economic Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale\u2013New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Knowledge Evaluation Research Unit, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"},{"name":"Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota"},{"name":"OptumLabs, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"zoi201072r3","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142020.","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi201072r5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary.","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"issue":"9","key":"zoi201072r6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.7326\/M17-1362","article-title":"Synopsis of the 2017 US Department of Veterans Affairs\/US Department of Defense Clinical Practice Guideline: management of type 2 diabetes mellitus.","volume":"167","author":"Conlin","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi201072r7","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society Clinical Practice Guideline.","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10193","key":"zoi201072r8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10193","key":"zoi201072r9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"zoi201072r10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"zoi201072r11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi201072r12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes.","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi201072r13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201072r14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi201072r15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201072r16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"zoi201072r17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201072r18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201072r19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi201072r20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk.","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"issue":"22","key":"zoi201072r21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi201072r23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the US\u2014the case of SGLT2 inhibitors: nationwide cohort study.","volume":"21","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"zoi201072r24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system.","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi201072r27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"zoi201072r29","article-title":"Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes.","author":"McCoy","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"zoi201072r30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19099","article-title":"Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes.","volume":"3","author":"McCoy","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi201072r32","first-page":"721","article-title":"Validating the adapted Diabetes Complications Severity Index in claims data.","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"4","key":"zoi201072r33","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/hesr.2007.42.issue-4","article-title":"Utilizing new prescription drugs: disparities among non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites.","volume":"42","author":"Wang","year":"2007","journal-title":"Health Serv Res"},{"issue":"6","key":"zoi201072r34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40615-016-0320-2","article-title":"Racial-ethnic disparities in uptake of new hepatitis C drugs in Medicare.","volume":"4","author":"Jung","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"issue":"6","key":"zoi201072r36","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/03007995.2020.1756764","article-title":"Sociodemographic disparities in the management of type 2 diabetes in the United States.","volume":"36","author":"Tan","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"zoi201072r37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/0898264319879608","article-title":"How are income and education related to the prevention and management of diabetes?","volume":"32","author":"Allen","year":"2020","journal-title":"J Aging Health"},{"issue":"1","key":"zoi201072r38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.18865\/ed.26.1.85","article-title":"Racial and economic disparities in diabetes in a large primary care patient population.","volume":"26","author":"Heidemann","year":"2016","journal-title":"Ethn Dis"},{"issue":"1","key":"zoi201072r39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0027-9684(15)30085-7","article-title":"Racial and ethnic disparities in diabetes complications in the northeastern United States: the role of socioeconomic status.","volume":"105","author":"Osborn","year":"2013","journal-title":"J Natl Med Assoc"},{"issue":"4","key":"zoi201072r40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s11606-011-1910-7","article-title":"The effects of financial pressures on adherence and glucose control among racial\/ethnically diverse patients with diabetes.","volume":"27","author":"Ngo-Metzger","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi201072r41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/003335491012500306","article-title":"Socioeconomic status and risk of diabetes-related mortality in the US.","volume":"125","author":"Saydah","year":"2010","journal-title":"Public Health Rep"},{"issue":"2","key":"zoi201072r42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.whi.2005.08.003","article-title":"Gender differences across racial and ethnic groups in the quality of care for diabetes.","volume":"16","author":"Correa-de-Araujo","year":"2006","journal-title":"Womens Health Issues"},{"key":"zoi201072r1","volume-title":"National Diabetes Statistics Report, 2020.","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"zoi201072r26","author":"OptumLabs"},{"key":"zoi201072r28","first-page":"74","volume-title":"National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) Comprehensive Diabetes Care","author":"National Committee for Quality Assurance","year":"2015"},{"key":"zoi201072r35","volume-title":"National Diabetes Statistics Report, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"zoi201072r2","unstructured":"Centers for Disease Control and Prevention. Diabetes data & statistics. Diabetes Atlas. Updated November 2020. Accessed July 21, 2020. https:\/\/gis.cdc.gov\/grasp\/diabetes\/DiabetesAtlas.html#"},{"key":"zoi201072r4","unstructured":"National Institute for Health and Care Excellence. NICE pathways: managing blood glucose in adults with type 2 diabetes. Updated December 16, 2020. Accessed December 17, 2020. https:\/\/pathways.nice.org.uk\/pathways\/type-2-diabetes-in-adults"},{"key":"zoi201072r22","unstructured":"Freed? M, Damico? A, Neuman? T. A dozen facts about Medicare Advantage in 2020. Published April 22, 2020. Accessed November 18, 2020. https:\/\/www.kff.org\/medicare\/issue-brief\/a-dozen-facts-about-medicare-advantage-in-2020\/"},{"key":"zoi201072r25","unstructured":"Optum. Optum research data assets. Published June 2015. Accessed July 16, 2019. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf"},{"key":"zoi201072r31","unstructured":"United Healthcare. 2021 prescription drug list: United Healthcare & affiliated companies. Posted 2020. Accessed December 5, 2020. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/resources\/pharmacy\/UHC-Commerical-PDL-Booklet-Eff-Jan-1-2021.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2775659\/mccoy_2021_oi_201072_1611250254.71775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T04:09:08Z","timestamp":1612238948000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2775659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.35792","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}